Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2010

View Archived Issues

Cempra's Taksta for acute skin infections shows efficacy, tolerability in phase II trials

PRISM Biolab identifies novel Wnt signaling pathway inhibitors

Orchid Chemicals & Pharmaceuticals describes novel HDAC inhibitors

Novel nAChR alpha4beta2 ligands claimed by PsychoGenics and Illinois University

Novel "two-in-one" antibody targeting EGFR/HER3 shows preclinical potential

Prostate cancer diagnostic 99mTc-EC-0652 to proceed to phase 0 clinical evaluation

Intermune describes NS3/NS4 protease inhibitors

NeuroSearch claims nicotinic alpha7 receptor ligands

CTS-1027 well tolerated in HCV patients failing prior treatments

Evotec and Genentech enter agreement to discover small-molecule therapeutics

Optovue obtains FDA clearance for iVue SD-OCT

Japanese phase I CNS-7056 trial commences, triggering milestone for PAION

Nile completes dose escalation in phase II CD-NP study in heart failure

Cleveland BioLabs completes dosing in second safety study for CBLB-502

Wnt signaling inhibitor CW-232291 to advance to phase I

Phase I safety data reported for orphan drug QPI-1002

MediGene signs license agreements with GC-Rise and JS Bio for Veregen

Proof-of-concept study in irritable bowel disease encourages larger studies with AST-120

Phase III and other data on morphine/oxycodone combination reported

Humenza well tolerated and immunogenic in children

Takeda and Janssen Pharmaceutical agree to copromote Velcade in Japan

Novartis to begin phase III studies of QVA-149 combination therapy for COPD

FDA accepts review of sBLA to expand indication of Menveo in children

Generex achieves enrollment of over 400 subjects in Generex Oral-lyn study

Acrux and Vivus sign settlement agreement for Luramist dispute, Vivus license terminated

CrystalGenomics completes phase I SAD study of antibiotic candidate CG-400549

NexACT technology shown to enhance bioavailability of rituximab in preclinical study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...